Orion Pharma, Sandoz Pharma Ltd. deal

Orion granted Sandoz U.S. marketing rights to entacapone, a COMT (Catechol-O-Methyltransferase) inhibitor in Phase III trials as an adjunct therapy to treat Parkinson's disease. Sandoz will make an upfront payment of $4.8 million and will pay undisclosed milestones. ...